Physiowave

Executive Summary

PhysioWave is an Australian med-tech company commercializing an FDA-cleared, scale-based device that measures pulse wave velocity (PWV) and other vital signs in under one minute. The device enables rapid, non-invasive arterial stiffness assessment, facilitating cardiovascular risk stratification in primary care and outpatient settings. Founded in 2020 and based in Melbourne, the company has an estimated 10–50 employees and operates at the commercial stage. By leveraging a familiar form factor (a scale) combined with proprietary algorithms, PhysioWave aims to lower barriers to routine arterial health screening, addressing a significant unmet need in preventive cardiology. The company's technology has the potential to shift cardiovascular risk assessment from specialized labs to everyday clinical practice, improving early detection of hypertension, arteriosclerosis, and related conditions. Despite a promising value proposition, PhysioWave faces challenges typical of early commercial med-tech firms: limited brand recognition outside Australia, need for clinical validation beyond initial clearance, and competition from established vascular assessment modalities (e.g., tonometry, ultrasound). The company's private status and lack of disclosed financials or pipeline details suggest it is still building commercial momentum. However, its FDA clearance provides a credible foundation for U.S. market entry, and growing interest in decentralized cardiovascular screening could accelerate adoption. Key near-term opportunities include expanding into the U.S. market, securing reimbursement codes, and generating further clinical evidence to support broader guideline inclusion.

Upcoming Catalysts (preview)

• Q2 2026U.S. Commercial Launch & Distribution Partnership70% success
• Q3 2026Publication of Multi-Center Clinical Validation Study80% success
• Q1 2027CE Mark Approval for European Market Entry60% success